hexanoic acid has been researched along with Alzheimer Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Du, J; Gao, C; He, G; He, Y; Huang, P; Li, B; Tang, H; Zhang, P | 1 |
| Dannhardt, G; Dehm, F; Flesch, D; Hieke, M; Lamers, C; Ness, J; Ogorek, I; Popella, S; Schubert-Zsilavecz, M; Steri, R; Weggen, S; Werz, O | 1 |
| Curran, GL; Fauq, AH; Khan, MA; McCormick, DJ; Peterson, JA; Poduslo, JF; Wengenack, TM | 1 |
3 other study(ies) available for hexanoic acid and Alzheimer Disease
| Article | Year |
|---|---|
Early changes of fecal short-chain fatty acid levels in patients with mild cognitive impairments.
Topics: Acetates; Alzheimer Disease; Amyloid beta-Peptides; Atrophy; Butyric Acid; Caproates; Cognitive Dysfunction; Fatty Acids, Volatile; Humans; Positron-Emission Tomography | 2023 |
SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Arachidonate 5-Lipoxygenase; Caproates; Humans; Lipoxygenase Inhibitors; PPAR gamma; Structure-Activity Relationship | 2015 |
Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Brain; Caproates; Contrast Media; Drug Design; Gadolinium DTPA; Humans; Magnetic Resonance Spectroscopy; Membrane Proteins; Mice; Mice, Transgenic; Molecular Structure; Peptide Fragments; Plaque, Amyloid; Presenilin-1; Spectrometry, Mass, Electrospray Ionization | 2004 |